NCT06924684View on ClinicalTrials.gov

High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

June 23, 2025

Study Completion Date

July 2, 2025

Conditions
ST Elevation (STEMI) Myocardial Infarction
Interventions
DRUG

Statin monotherapy (rosuvastatin or atorvastatin)

Tab Rosuvastatin 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.

DRUG

Placebo

Placebo caspule

Trial Locations (2)

54600

Shaikh Zayed Hsopital, Lahore

Unknown

Punjab Institute of Cardiology, Lahore

All Listed Sponsors
collaborator

Punjab Institute of Cardology

OTHER

lead

Sheikh Zayed Federal Postgraduate Medical Institute

OTHER

NCT06924684 - High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI | Biotech Hunter | Biotech Hunter